torcetrapib has been researched along with dalcetrapib in 53 studies
| Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (dalcetrapib) | Trials (dalcetrapib) | Recent Studies (post-2010) (dalcetrapib) |
|---|---|---|---|---|---|
| 273 | 28 | 83 | 166 | 38 | 103 |
| Protein | Taxonomy | torcetrapib (IC50) | dalcetrapib (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 4.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (32.08) | 29.6817 |
| 2010's | 35 (66.04) | 24.3611 |
| 2020's | 1 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, TP; Borel, A; Cannady, EA; Cao, G; Cockerham, SL; Escribano, A; Fernandez, MC; Frank, S; Jones, TM; Mantlo, NB; Martin de la Nava, EM; Mateo, AI; Parthasarathy, S; Schmidt, RJ; Stephenson, G; Sweetana, SA; Wang, X; Zhang, Y | 1 |
| Cao, G; Chang, Y; Chen, D; He, X; Huang, X; Liu, J; Luo, H; Ni, S; Shen, Q; Sun, H; Wang, P; Wen, X; Zhou, H | 1 |
| Brousseau, M; Honma, W; Iimura, A; Imase, H; Iwaki, Y; Kawanami, T; LaSala, D; Liang, G; Mitani, H; Mogi, M; Nonomura, K; Ohmori, O; Pan, M; Rigel, DF; Umemura, I; Yamada, K; Yasoshima, K; Zhu, G | 1 |
| Maeda, K; Okamoto, H; Shinkai, H | 1 |
| Boekholdt, SM; Hovingh, GK; Kastelein, JJ; Klerkx, AH; Kuivenhoven, JA; van der Steeg, WA | 1 |
| Barter, PJ; Kastelein, JJ | 1 |
| Clark, RW | 1 |
| El-Harchaoui, K; Kastelein, JJ; Kuivenhoven, JA; Van der Steeg, WA | 1 |
| Chapman, MJ | 1 |
| Asztalos, BF; Schaefer, EJ | 1 |
| El Harchaoui, K; Kastelein, JJ; Stroes, ES; van der Steeg, WA | 1 |
| Hegele, RA; Joy, T | 2 |
| Athyros, VG; Kakafika, A; Karagiannis, A; Mikhailidis, DP; Tziomalos, K | 1 |
| Rennings, AJ; Stalenhoef, A | 1 |
| Potter, LK; Sprecher, DL; Tobin, FL; Walker, MC | 1 |
| Buckley, BM; Burgess, T; Capponi, AM; Kallend, D; Kastelein, JJ; Niesor, EJ; Stein, EA; Steiner, G; Stroes, ES | 1 |
| Shinkai, H | 2 |
| Stroes, ES; Vergeer, M | 1 |
| Bénardeau, A; Blum, D; Campos, LA; Clerc, RG; Kastelein, JJ; Kuhlmann, O; Niesor, EJ; Stroes, ES | 1 |
| Böhm, M; Laufs, U; Pöss, J | 1 |
| Rosenson, RS | 1 |
| Addona, G; Bierilo, KK; Chen, Q; Chen, Y; Elowe, NH; Eveland, S; Fisher, TS; Frantz-Wattley, B; Garcia-Calvo, M; Houde, C; Hubbard, B; Kavana, M; Koblan, KS; Milot, D; O'Neill, EA; Porter, G; Ranalletta, M; Sinclair, P; Sitlani, A; Sparrow, C; Tung, E | 1 |
| Bénardeau, A; Capponi, AM; Clerc, RG; Funder, JW; Garriz, JM; Hainaut, E; Hoflack, JC; Niesor, EJ; Perez, A; Pflieger, P; Stauffer, A; Weibel, F | 1 |
| Miura, S; Saku, K | 1 |
| Hausenloy, DJ; Opie, L; Yellon, DM | 1 |
| Blum-Kaelin, D; Chaput, E; Clerc, RG; Dernick, G; Huber, W; Kakutani, M; Magg, C; Matile, H; Maugeais, C; Niesor, EJ; Ogawa, N; Okamoto, H; Pflieger, P; Schmid, G; Takahashi, D; Thoma, R; von der Mark, E | 1 |
| Katsnelson, A | 1 |
| Niesor, EJ | 1 |
| Blum, D; Chaput, E; Derks, M; Kallend, D; Niesor, EJ; Staempfli, A | 1 |
| Ghosh, RK; Ghosh, SM | 1 |
| Fisher, EA; Hewing, B | 1 |
| Deanfield, J; Kastelein, J; Landmesser, U; Lüscher, TF; von Eckardstein, A | 1 |
| Duivenvoorden, R; Fayad, ZA | 1 |
| Taylor, J | 1 |
| Schaefer, EJ | 1 |
| Akhlaghi, F; Mohammadpour, AH | 1 |
| Cai, J; Chen, C; Hu, Z; Li, C; Li, Y; Liu, L; Luo, H; Pei, F; Zeng, C; Zhang, W; Zhou, F; Zhou, L | 1 |
| deGoma, EM; Rader, DJ | 1 |
| Francis, DP; Keene, D; Price, C; Shun-Shin, MJ | 1 |
| McCullough, PA; Shin, HJ | 1 |
| Sloop, GD; St Cyr, JA; Weidman, JJ | 1 |
| Even, S; Montezano, AC; Neves, KB; Nguyen Dinh Cat, A; Palacios, R; Rios, FJ; Touyz, RM | 1 |
| Barter, PJ; Kastelein, JJ; Nicholls, SJ; Rye, KA | 1 |
| Boekholdt, SM; Hovingh, GK; Ray, KK | 1 |
| Quintão, EC | 1 |
| Barkas, F; Elisaf, M; Filippatos, TD; Klouras, E | 1 |
| Avorn, J; Franklin, JM; Hey, SP; Kesselheim, AS | 1 |
| Charles, MA; Johns, DG; Krauss, RM; Lei, D; Peng, B; Ren, G; Rye, KA; Yang, M; Zhang, L; Zhang, M | 1 |
| Corsini, A; Macchi, C; Matsuzawa, Y; Ruscica, M; Sirtori, CR; Yamashita, S | 1 |
| Bis, JC; Charoen, P; Chaturvedi, N; Drenos, F; Finan, C; Franceschini, N; Gaunt, TR; Giambartolomei, C; Gordillo-Marañón, M; Hingorani, AD; Hughes, AD; Hunt, NB; Kivimaki, M; Lawlor, DA; Mook-Kanamori, DO; O'Donnell, CJ; Papacosta, O; Price, JF; Schmidt, AF; Sofat, R; Wannamethee, G; Wong, A; Zwierzyna, M | 1 |
28 review(s) available for torcetrapib and dalcetrapib
| Article | Year |
|---|---|
Role of CETP inhibitors in the treatment of dyslipidemia.
Topics: Amides; Animals; Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Glycoproteins; Humans; Hyperlipidemias; Hypolipidemic Agents; Quinolines; Sulfhydryl Compounds | 2004 |
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Topics: Amides; Animals; Atherosclerosis; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Esters; Glycoproteins; Humans; Quinolines; Risk Factors; Sulfhydryl Compounds; Vaccines | 2006 |
Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
Topics: Amides; Atherosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Female; Glycoproteins; Humans; Lipoproteins, HDL; Male; Quinolines; Sulfhydryl Compounds | 2006 |
Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?
Topics: Amides; Atherosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Glycoproteins; Humans; Models, Biological; Quinolines; Sulfhydryl Compounds | 2005 |
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Topics: Amides; Animals; Atherosclerosis; Biological Transport; Cholesterol; Cholesterol, HDL; Coronary Disease; Esters; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; PPAR alpha; PPAR delta; PPAR gamma; Quinolines; Sulfhydryl Compounds | 2006 |
Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
Topics: Amides; Animals; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Glycoproteins; Humans; Lipid Metabolism; Lipoproteins, HDL; Quinolines; Risk; Sulfhydryl Compounds | 2006 |
The role of CETP inhibition in dyslipidemia.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Dyslipidemias; Esters; Female; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Male; Quinolines; Sulfhydryl Compounds | 2007 |
Is raising HDL a futile strategy for atheroprotection?
Topics: Amides; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Atherosclerosis; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Humans; Lipoproteins, HDL; Phospholipids; Quinolines; Sulfhydryl Compounds; Treatment Outcome | 2008 |
JTT-705: is there still future for a CETP inhibitor after torcetrapib?
Topics: Amides; Animals; Anticholesteremic Agents; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Esters; Humans; Quinolines; Sulfhydryl Compounds | 2008 |
The end of the road for CETP inhibitors after torcetrapib?
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2009 |
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Esters; Humans; Oxazolidinones; Patents as Topic; Quinolines; Sulfhydryl Compounds | 2009 |
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Topics: Aldosterone; Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Corticosterone; Esters; Humans; Hydrocortisone; Hypercholesterolemia; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2009 |
[HDL and CETP in atherogenesis].
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Nicotinic Acids; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome | 2010 |
Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Humans; Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2011 |
Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Hyperlipidemias; Oxazolidinones; Quinolines; Risk Factors; Sulfhydryl Compounds | 2012 |
Rationale for cholesteryl ester transfer protein inhibition.
Topics: Amides; Animals; Benzodiazepines; Cholesterol Ester Transfer Proteins; Drug Discovery; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2012 |
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Topics: Amides; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Esters; Humans; Hypolipidemic Agents; Oxazolidinones; Quinolines; Sulfhydryl Compounds; Treatment Outcome | 2012 |
Safety of CETP inhibition.
Topics: Amides; Animals; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Oxazolidinones; Quinolines; Safety; Sulfhydryl Compounds | 2012 |
Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Topics: Amides; Anticholesteremic Agents; Apolipoproteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Lipid Metabolism; Protein Binding; Quinolines; Sulfhydryl Compounds; Treatment Failure; Triglycerides | 2013 |
Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
Topics: Adult; Amides; Anticholesteremic Agents; Benzodiazepines; Blood Pressure; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome; Triglycerides | 2013 |
Future of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2014 |
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Myocardial Infarction; Niacin; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Stroke; Sulfhydryl Compounds | 2014 |
Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Topics: Amides; Apolipoprotein A-I; Benzodiazepines; Black or African American; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Esters; Heart Diseases; Humans; Hyperlipoproteinemias; Kidney Diseases; Liver; Niacin; Observational Studies as Topic; Oxazolidinones; Prospective Studies; Quinolines; Randomized Controlled Trials as Topic; Risk; Sulfhydryl Compounds; Triglycerides; White People | 2014 |
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
Topics: Amides; Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Hypercholesterolemia; Mice; Oxazolidinones; Quinolines; Rabbits; Sulfhydryl Compounds | 2016 |
Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Esters; Humans; Lipids; Lipoprotein(a); Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2016 |
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Biomarkers, Pharmacological; Cholesterol Ester Transfer Proteins; Drug Approval; Drug Discovery; Dyslipidemias; Endpoint Determination; Esters; Humans; Lipids; Oxazolidinones; Predictive Value of Tests; Quinolines; Reproducibility of Results; Sulfhydryl Compounds; Time Factors; Treatment Outcome | 2017 |
Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Lignans; Lipoproteins, HDL; Lipoproteins, VLDL; Oxazolidinones; Probucol; Quinolines; Sulfhydryl Compounds; Triglycerides | 2018 |
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Humans; Mendelian Randomization Analysis; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2021 |
2 trial(s) available for torcetrapib and dalcetrapib
| Article | Year |
|---|---|
Safety and tolerability of dalcetrapib.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Esters; Female; Humans; Incidence; Male; Middle Aged; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds | 2009 |
Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Cholestanol; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Cross-Over Studies; Desmosterol; Esters; Ezetimibe; Homeostasis; Humans; Intestinal Absorption; Lipid Metabolism; Male; Mesocricetus; Models, Animal; Phytosterols; Quinolines; Sitosterols; Sulfhydryl Compounds; Switzerland | 2011 |
23 other study(ies) available for torcetrapib and dalcetrapib
| Article | Year |
|---|---|
Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Topics: Animals; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Dose-Response Relationship, Drug; Drug Design; Humans; Inhibitory Concentration 50; Mice; Naphthyridines; Structure-Activity Relationship | 2012 |
Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
Topics: Animals; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Drug Discovery; Esters; Guinea Pigs; Humans; Mice; Mice, Transgenic; Molecular Structure; Structure-Activity Relationship; Triterpenes | 2017 |
Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma.
Topics: Aged; Animals; Chick Embryo; Cholesterol Ester Transfer Proteins; Humans; Hypertriglyceridemia; Male; Mesocricetus; Piperidines; Rats; Structure-Activity Relationship | 2017 |
S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors.
Topics: Amides; Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Glycoproteins; Humans; Inhibitory Concentration 50; Protective Agents; Quinolines; Structure-Activity Relationship; Sulfhydryl Compounds | 2004 |
Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
Topics: Amides; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Drug Design; Drug Therapy, Combination; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Quinolines; Sulfhydryl Compounds; Up-Regulation | 2008 |
Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.
Topics: Algorithms; Amides; Animals; Anticholesteremic Agents; Binding Sites; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Computer Simulation; Esters; Humans; Kinetics; Models, Biological; Quinolines; Sulfhydryl Compounds; Triglycerides | 2009 |
Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats.
Topics: Adrenal Glands; Amides; Animals; Anticholesteremic Agents; Aorta; Blood Pressure; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Esters; Heart Rate; Hemodynamics; Male; Polymerase Chain Reaction; Quinolines; Rats; Rats, Inbred SHR; Rats, Wistar; Renin-Angiotensin System; RNA, Messenger; Sulfhydryl Compounds | 2009 |
Functional assessment of HDL: Moving beyond static measures for risk assessment.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds | 2010 |
Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Animals; Anticholesteremic Agents; Blood Proteins; Cholesterol Ester Transfer Proteins; Esters; Humans; Mice; Molecular Structure; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2010 |
Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Topics: Adrenal Cortex; Adrenal Gland Neoplasms; Aldosterone; Amides; Angiotensin II; Animals; Anticholesteremic Agents; Blood Pressure; Calcium; Calcium Channels, L-Type; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cytochrome P-450 CYP11B2; Cytosol; Enzyme Induction; Esters; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Gene Expression Profiling; Humans; Hypertension; NAV1.1 Voltage-Gated Sodium Channel; Nerve Tissue Proteins; Quinolines; Rats; Rats, Inbred SHR; RNA, Small Interfering; Sodium Channels; Structure-Activity Relationship; Sulfhydryl Compounds | 2010 |
Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
Topics: Amides; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Esters; Humans; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds | 2010 |
Dissociating HDL cholesterol from cardiovascular risk.
Topics: Amides; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Predictive Value of Tests; Primary Prevention; Quinolines; Risk Assessment; Risk Factors; Secondary Prevention; Sulfhydryl Compounds | 2010 |
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Topics: Amides; Animals; Anticholesteremic Agents; Bile Acids and Salts; Binding Sites; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Cricetinae; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Esters; High-Density Lipoproteins, Pre-beta; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2010 |
Good news for 'good' cholesterol.
Topics: Amides; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2010 |
Learning lessons from Pfizer's $800 million failure.
Topics: Amides; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Industry; Esters; Humans; Quinolines; Sulfhydryl Compounds | 2011 |
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
Topics: Acute Coronary Syndrome; Amides; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Early Termination of Clinical Trials; Esters; Humans; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds | 2012 |
CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit.
Topics: Amides; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Fibric Acids; Humans; Hypolipidemic Agents; Niacin; Quinolines; Sulfhydryl Compounds | 2013 |
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2013 |
Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity?
Topics: Amides; Anticholesteremic Agents; Blood Pressure; Blood Viscosity; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Erythrocyte Aggregation; Esters; Humans; Quinolines; Sulfhydryl Compounds; Treatment Failure | 2015 |
Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Topics: Adipocytes; Aldosterone; Amides; Animals; Cell Line; Cholesterol Ester Transfer Proteins; Esters; Humans; Mice; NADPH Oxidases; Oxazolidinones; Phosphorylation; Quinolines; Reactive Oxygen Species; STAT3 Transcription Factor; Sulfhydryl Compounds | 2015 |
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome | 2015 |
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome | 2015 |
Assessing the mechanisms of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Cholesterol Ester Transfer Proteins; Esters; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Multiprotein Complexes; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2017 |